Vaccine Design pp 147-153 | Cite as

Iscoms as Mucosal Vaccine Vectors

  • Allan McI.Mowat
  • Kevin J. Maloy
  • Rosemary E. Smith
  • Anne M. Donachie
Part of the NATO ASI Series book series (NSSA, volume 293)


There is currently a great deal of interest in developing orally active synthetic vaccines containing recombinant proteins as protective antigens. However, purified proteins are poorly immunogenic in general and do not elicit the mucosal immunity essential for protecting against diseases of mucosal surfaces such as the intestine and respiratory tract (McGhee et al 1992). Indeed, the usual result of administering soluble proteins by the oral route is profound immunological tolerance which prevents systemic and local immune responses on subsequent exposure to the antigen (Mowat 1987). Thus there is a need for vectors that will avoid this phenomenon of oral tolerance and prime a full range of immune responses to orally administered protein antigens.


Oral Tolerance Systemic Immune Response Mucosal Immune Response Peritoneal Exudate Cell Oral Immunisation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Araujo, F.G. and Morein, B.1991, Immunisation with Trypanosoma cruzi epimastigote antigens incorporated into ISCOMS protects against lethal challenge in mice. Infect. Immun., 59: 2909.PubMedGoogle Scholar
  2. Claasen, I. and Osterhaus. A., 1992, The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Res. Immunol., 143: 531.CrossRefGoogle Scholar
  3. Garside, P., M. Steel, E.A. Worthey, A. Satoskar, J. Alexander, H. Bluethmann, F.Y. Liew, and A.MeI Mowat. 1995, Th2 cells are subject to high dose oral tolerance and are not essential for its induction. J Immunol., 154: 5649.PubMedGoogle Scholar
  4. Heeg, K., Kuon, W. and Wagner, H., 1991, Vaccination of Class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes toward soluble antigen: immunostimulating complexes enter the Class 1 MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur.J.Immunol., 21: 152.CrossRefGoogle Scholar
  5. Kersten, G.F.A., Spiekstra, A., Beuvery, E.C. and Crommelin, D.J.A., 1991, On the structure of immune-stimulating saponin-lipid complexes (ISCOMS). Bioch.Bioph.Acta. 1062: 165.CrossRefGoogle Scholar
  6. Maloy, K.J., Donachie, A.M. and Mowat, A.McI., 1995, Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol., 25: 2835.PubMedCrossRefGoogle Scholar
  7. McGhee, J.R., Mestecky, J., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, H., 1992, The mucosal immune system: from fundamental concepts to vaccine development. Vaccine, 10, 75.PubMedCrossRefGoogle Scholar
  8. Morein, B., Fossum, C., Lovgren, K. and Hoglund, S., 1990, The ISCOM-a modern approach to vaccines. Semin. Virol., 1: 49.Google Scholar
  9. Morein, B., Lövgren, K., Rönnberg, B., Sjölander, A. and Villacres-Eriksson, M., 1995, Immunostimulating complexes. Clinical potential in vaccine development. Clin. Immunother., 3: 461.CrossRefGoogle Scholar
  10. Mowat, A.McI, 1987, The regulation of immune responses to dietary protein antigens. Immunology Today. 8: 93.CrossRefGoogle Scholar
  11. Mowat, A.McI., Donachie, A.M., Reid, G. and Jarrett, O., 1991, Immune stimulating complexes containing Quil A and protein antigen prime Class I MHC-restricted T lymphocytes in vivo and are active by the oral route. Immunology. 72, 317.PubMedGoogle Scholar
  12. Mowat, A. McI, Maloy, K.J. and Donachie, A.M., 1993, Immune stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunisation with protein antigens. Immunology, 80: 527.PubMedGoogle Scholar
  13. Mowat, A. MeI. and Reid, G., 1994, The preparation of immune stimulating complexes (ISCOMS) as adjuvants for local and systemic immunisation with protein antigens. In; “Current Protocols in Immunology”, J.E. Coligan Kruisbeek, A.M., Margulies, D., Shevach, E. and Strober, W.v eds., John Wiley and Sons Inc, New York.Google Scholar
  14. Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao. S., Matthaei, K. I., Koehler, G. and Kopf, M., 1994, The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 264: 561.PubMedCrossRefGoogle Scholar
  15. Takahashi, H., T. Takeshita, B. Morein, S. Putney, R.N. Germain, and J. Berzofsky, 1990, Induction of CD8+ cytotoxic T cells by immunisation with purified HIV-1 envelope protein in ISCOMS. Nature, 344: 873–5.PubMedCrossRefGoogle Scholar
  16. Trudel, M., Nadon, F., Seguin, C., Brault, S., Lusignan, Y. and Lemieux, S., 1992, Initiation of cytotoxic T cell response and protection of BALB/c mice by vaccination with an experimental ISCOMS respiratory syncytial virus subunit vaccine. Vaccine, 10: 107.PubMedCrossRefGoogle Scholar
  17. Vajdy, M., Kosco-Vilbois, M.H., Kopf, M., Kohler, G. and Lycke, N., 1995, Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med., 181: 41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Allan McI.Mowat
    • 1
  • Kevin J. Maloy
    • 1
  • Rosemary E. Smith
    • 1
  • Anne M. Donachie
    • 1
  1. 1.Department of Immunology, Western InfirmaryUniversity of GlasgowGlasgowUK

Personalised recommendations